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Abstract
Background: Batch effects were not accounted for in most of the studies of computational drug repositioning
based on gene expression signatures. It is unknown how batch effect removal methods impact the results of
signature-based drug repositioning. Herein, we conducted differential analyses on the Connectivity Map (CMAP)
database using several batch effect correction methods to evaluate the influence of batch effect correction
methods on computational drug repositioning using microarray data and compare several batch effect correction
methods.
Results: Differences in average signature size were observed with different methods applied. The gene
signatures identified by the Latent Effect Adjustment after Primary Projection (LEAPP) method and the
methods fitted with Linear Models for Microarray Data (limma) software demonstrated little agreement. The
external validity of the gene signatures was evaluated by connectivity mapping between the CMAP database
and the Library of Integrated Network-based Cellular Signatures (LINCS) database. The results of connectivity
mapping indicate that the genes identified were not reliable for drugs with total sample size (drug + control
samples) smaller than 40, irrespective of the batch effect correction method applied. With total sample size
larger than 40, the methods correcting for batch effects produced significantly better results than the method
with no batch effect correction. In a simulation study, the power was generally low for simulated data with
sample size smaller than 40. We observed best performance when using the limma method correcting for
two principal components.
Conclusion: Batch effect correction methods strongly impact differential gene expression analysis when the
sample size is large enough to contain sufficient information and thus the downstream drug repositioning.
We recommend including two or three principal components as covariates in fitting models with limma
when sample size is sufficient (larger than 40 drug and controls combined).
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Background
Drug repositioning is the process of finding new indi-
cations for existing drugs. If successful, it has advan-
tages over de novo drug development in terms of
potentially shorter development times, less costs and risks
[1]. Facilitated by recent growth of high-throughput omics
data, computational methods in drug repositioning have
been developed, which provide researchers efficient routes
to explore a large number of drugs and diseases simultan-
eously [2]. Many in silico drug repositioning approaches
have been developed during the past decades, which can
be broadly classified into target-based, expression-based,
knowledge-based, chemical structure-based, pathway-
based and mechanism of action-based [3]. Here, we focus
on gene expression-based approaches which require gene
expression signatures derived from the data itself and re-
quire little a priori knowledge on diseases or drugs. A gene
expression signature is a set of genes that are significantly
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up- or down-regulated by certain biological process or
pathological medical condition as compared to a control
condition. A popular approach is to identify new indica-
tions for drugs based on their gene signature showing an
opposite pattern of up−/down-regulation as compared to
a disease signature [4]. This approach was piloted by the
Connectivity Map (CMAP) project, in which a pattern
matching algorithm was employed to rank the similarities
between the query signature and the compound profiles
called reference signatures [5]. Several studies have used
this resource and applied a similarity based approach for
drug repositioning [6–10]. For example, Sirota et al. inte-
grated 164 drug compounds from CMAP and 100 diseases
to predict novel therapeutic indications on signatures in
drug-disease pairs, which have led to the discovery of ci-
metidine as a candidate treatment for lung adenocarcin-
oma [7]. As another example, Van Noort et al. utilized the
gene expression profiles of more than 1000 drugs from
CMAP and applied the inverse signature approach to
identify anti-metastatic drugs for the treatment of colorec-
tal cancer [11]. The follow-up database to CMAP is the
Library of Integrated Network-based Cellular Signatures
(LINCS) L1000 database [12], which has been recently
used in signature-based drug repositioning [13].
Despite CMAP having been demonstrated to be valu-
able and successful, it still has some limitations. These
include a limited number of cell-lines and the fact that
batches were required to generate all the data. Both fac-
tors can lead to biased analyses and here we focus on
batch effects. Batch effects are defined as technical varia-
tions that have been introduced by time varying external
factors during handling of the samples or effects of sam-
ple handling itself. Such factors include various sources,
such as personnel effects, environmental conditions, dif-
ferent experiment times, etc. [14], some of which can be
minimized by careful experimental design, while some
are impossible to be completely avoided in practice.
Whether batch effects were properly adjusted for can
potentially affect the validity of the generated gene sig-
natures as well as the power of the analysis to find dif-
ferentially expressed genes [15, 16]. Many batch effect
correction methods have been developed and were
reviewed by Lazar et al. [17]. COMBAT (combining
batches of microarray data) applies Empirical Bayes esti-
mation to adjust the mean and the variance by pooling
information across multiple genes in order to perform
gene-wise batch corrections for mean and variance [18],
which is an example for methods focusing on mean ad-
justments. Guided PCA (gPCA) performs a model selec-
tion on batch indicators/covariates known to impact
measurements which is interesting when study design is
complex and many potential factors that can influence
the measurement process have been recorded. RUV-2
(“Remove Unwanted Variation, 2-step”) makes use of
negative control genes that are a priori known to be un-
correlated with the biological effects of interest to iden-
tify the factors associated with batch effects, and further
adjusts for these factors [19]. While RUV-2 relies on the
quality of the control genes selected, the Latent Effect
Adjustment after Primary Projection (LEAPP) method
was developed to statistically isolate the batch effects
from biological effect of interest, which in essence means
that control genes are automatically selected [20]. Surro-
gate variable analysis (SVA) explicitly tries to define a
subspace orthogonal to the outcome variable on which a
principal component analysis (PCA), or an analogous
singular value decomposition (SVD), is computed. In
spirit, therefore, SVA is almost identical to LEAPP which
performs the same decomposition but uses a slightly dif-
ferent model. RUV-2, LEAPP and SVA rely on principal
components (PCs), explicitly or implicitly, to describe
batch effects and can potentially correct for complex
and non-linear batch effects.
However, in many drug repositioning studies, gene ex-
pression profiles were directly used from either CMAP
or LINCS without correcting for batch effects [3, 6, 7,
10, 13]. Otherwise, mean centering was used to correct
for batch effects (Noort et al. [11]). Koudijs et al. cor-
rected for batch effects by blocking on batch id [4]. The
impact of batch effect correction methods on computa-
tional drug repositioning efforts using these data re-
sources, and their final impact on downstream drug
repositioning pipelines has not been analysed.
In this study, we aim to investigate the influence of
batch effect removal methods on computational drug
repositioning focusing on microarray data, using the
example of the CMAP dataset, since this is still the
primary source of drug gene expression signatures.
We conduct comparisons between several batch effect
correction methods, including correcting for batch id
and correcting for PCs in linear models fitted by
limma, and the LEAPP method. We evaluate the
quality of the gene signatures generated by these
methods by gene set enrichment analyses on the
shared drugs between the CMAP database and the
LINCS database (Fig. 1a). We further perform a simu-
lation study to examine the validity of the batch effect
correction methods (Fig. 1b).
Results
Differential expression analysis
Figure 2 gives an overview of the distribution of sam-
ple sizes in CMAP dataset. Most of the drugs (55%)
have total sample size between 20 to 30, while only a
small fraction of drugs (3%) has total sample size
more than 40. The scatter plot (Fig. 2b) shows that
there are more control samples than drug samples for
most of the drugs.
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Principal component analysis (PCA) was performed
for every gene expression data matrix jointly for the
treatment and control gene expression profiles corre-
sponding to each drug. As is shown in Fig. 3a, the me-
dian variance explained by the first 2 PCs decreases with
total sample size, from 62% (equal or below 20 samples)
to 48% (above 40 samples). The samples clearly cluster
by batch, but not by drug or control status (Fig. 3b-e).
However, it should be noted that in CMAP batch and
cell type are completely confounded for most drugs
(Additional file 1: Figure S1).
Gene expression differences between drugs and vehicle
controls were analyzed with linear models fitted by the
limma package (version 3.32.5). The null model always
contained the log-transformed concentrations. Subse-
quently, we tested if adding either the batch id or PCs im-
proves the external validity of the genes identified as
differentially expressed, as discussed below in the section
on connectivity mapping. We included several sets of co-
variates to adjust for batch effects: i) null; ii) batch id (corre-
sponding to the plate id); iii) one or more largest PCs
(continuous variable). The linear associations between
CMAP LINCS
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Fig. 1 Overall workflow of the study. a, workflow of real data analysis. CMAP and LINCS datasets are analyzed by principal component analysis,
followed by differential expression analysis with several batch effect correction methods, which were then evaluated by connectivity mapping
(the procedure of connectivity mapping is illustrated by Additional file 2: Figure S2); b, workflow of simulation analysis. Expression data were
simulated from CMAP dataset, and the optimal number of largest principal components being corrected for was assessed
Fig. 2 Summary plots of sample sizes in CMAP dataset. a, total (drug + control) sample size distribution in CMAP dataset. b, scatter plot of the
relationship between control sample size and drug sample size for CMAP dataset. Note: the total number of drugs in CMAP dataset is 1309. In
plot B, the drug trichostatin A (128 drug samples and 709 control samples) was not plotted because the particularly large sample size prevents a
zoomed in view of other drugs
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features and the drugs were also assessed by fitting models
with the LEAPP method, for which no batch information
was provided.
After filtering out the genes with coefficients of
variation outside the 20 and 80% quantiles, the num-
ber of genes included in the differential expression
analysis decreased to 8131. Due to insufficient sample
size, which did not allow some linear models to be
fitted, some of the drugs do not have results pro-
duced in differential expression analysis, as illustrated
in Table 1. The models fitted by LEAPP produced
the largest percentages of results of drug signature
size greater than or equal to 10 at any FDR < 100%,
but the average signature size produced by the
method was smaller than those generated by the
methods respectively correcting for batch id, three or
four PCs using limma (Fig. 4). Comparing among the
methods using limma, correcting for batch id yielded
largest percentages of results with drug signature size
greater than or equal to 10 at any FDR ≤ 60%,
followed by correcting for four PCs, and the percent-
ages decreased with fewer PCs being included in the
model (Fig. 4a). Similarly, the models fitted by limma
with correction for batch id produced greatest average
signature size and that with no correction yielded the
smallest average signature size at any FDR < 100%
(Fig. 4b). Table 2 summarizes the average number of
Fig. 3 Results of principal component analysis on expression matrices for CMAP dataset. a, Median variance accounted for by the four largest
principal components grouped by total sample size. b-e, Score plots of the first two principal components for four typical drugs; colors indicate
batch (plate id) and shapes indicate drug or control status
Table 1 Number of drugs in CMAP dataset which yielded gene
differential expression results by each method
Method Number of results
limma+ Null 1288 (98.4%)
limma+1PC 1288 (98.4%)
limma+2PCs 1271 (97.1%)
limma+3PCs 1270 (97.0%)
limma+4PCs 1236 (94.4%)
limma + Batch id 1288 (98.4%)
LEAPP 1254 (95.8%)
Note: percentage out of 1309 drugs in parentheses
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shared differentially expressed genes generated by dif-
ferent methods for CMAP dataset at FDR ≤ 10%. In
general, if two methods both show larger average sig-
nature size, they tend to share a higher percentage of
shared genes as compared to other pairs of methods.
Notably, we observed less agreement between the
LEAPP method and the limma methods than the
agreement between the methods that fit models using
limma and use different sets of covariates. The
LEAPP method resulted in many estimates that were
exactly zero, even for genes that were considered sta-
tistically significant by LEAPP (FDR ≤ 10%), indicating
numeric convergence problems, which prevented
meaningful gene set enrichment analysis. Therefore,
these results were not further analyzed.
Connectivity mapping
To evaluate the batch effect correction methods on real
data, as well as to mimic real practice drug repositioning
utilizing gene expression-based approach, we used the
CMAP drug signatures as input to identify the LINCS
drug signatures using the relative connectivity score
(with higher scores denoting higher similarities) calcu-
lated by Gene Set Enrichment Analysis using function
ConnectivityScore implemented in PharmocoGx package
[21]. For each comparison, the LINCS drug signatures
were processed based on the drugs and the genes shared
with the CMAP database using the same gene filtering
criteria and the same batch effect correction method. If
the method indeed improves the quality of the drug sig-
natures, the relative rank of drug signatures of the same
drug should increase after applying the method (Add-
itional file 2: Figure S2). The LINCS dataset shares 962
drugs and 883 genes with CMAP dataset. After applying
the same criteria of filtering, the overlapping number of
genes used in differential expression analysis was 529. In
the gene set enrichment analysis, when the gene set was
limited to 15 genes with the lowest FDR values, the
mean ranks of the drug signatures of the same drugs
ranged between 250 to 500 in the groups of drugs with
Fig. 4 Results of differential expression analysis on CMAP dataset. a, percentage of drugs having signature size greater than or equal to 10 for
each gene expression analysis method plotted against FDR cutoff. b, average signature size resulted from each gene expression analysis method
plotted against FDR cutoff; y-axis was transformed to log-10 scale
Table 2 Average number of shared differentially expressed genes found by different methods for the CMAP dataset (FDR ≤ 10%)
Method limma+Null limma+1PC limma+2PCs limma+3PCs limma+4PCs limma+Batch id LEAPP
Limma+Null (ASS = 50) 44 (37.3%) 27 (20.0%) 18 (14.9%) 14 (14.1%) 49 (19.6%) 9 (11.0%)
limma+1PC 44 (88.0%) (ASS = 118) 61 (45.2%) 39 (32.2%) 28 (18.2%) 106 (42.4%) 15 (18.3%)
limma+2PCs 27 (54.0%) 61 (51.7%) (ASS = 135) 81 (66.9%) 55 (55.6%) 120 (48.0%) 17 (20.7%)
limma+3PCs 18 (36.0%) 39 (33.1%) 81 (60.0%) (ASS = 121) 70 (70.7%) 100 (40.0%) 17 (20.7%)
limma+4PCs 14 (28.0%) 28 (23.7%) 55 (40.7%) 70 (57.9%) (ASS = 99) 75 (30.0%) 15 (18.3%)
limma+Batch id 49 (98.0%) 106 (89.8%) 120 (88.9%) 100 (82.6%) 75 (75.8%) (ASS = 250) 25 (30.5%)
LEAPP 9 (18.0%) 15 (12.7%) 17 (12.6%) 17 (14.0%) 15 (15.2%) 25 (10.0%) (ASS = 82)
Abbreviations: ASS = Average signature size (removed missing values)
Note: The table contains the number of differentially expressed genes that are shared between each pair of methods on the CMAP dataset. The numbers on the
diagonal indicate the average number of differentially expressed genes found by the respective methods. For the LEAPP method, the significant genes with
estimate = 0 were ignored. Percentages in parentheses are the proportions of the number of shared genes to average signature size produced by the method on
the column header
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total sample size less than or equal to 40 for every
method compared between CMAP dataset and LINCS
dataset (Fig. 5a). The results improved dramatically in
the group of drugs with total sample size greater than
40, in which the mean ranks ranged within 50 for limma
methods correcting either for two, three or four PCs, or
batch id (Fig. 5a). The methods correcting for two and
three PCs and batch id were equivalent or significantly
better than not correcting for batch effects or correcting
for only one PC (P < 0.05). The superior performance of
sample size > 40 is further demonstrated by the plot of
the high proportion of drugs (19–36%) having the con-
nectivity scores of the same drugs ranked within top 3
for every method stratified by group, compared to the
low proportion of drugs within rank 3 (2–13%) observed
in the group with sample size ≤40 (Fig. 4b). When the
cut-off rank was relaxed from top 3 to top 10, similar re-
sults were obtained (Additional file 3: Figure S3).
We also performed the gene set enrichment analysis
using sets of significant genes with FDR ≤ 10% and the
results are plotted on Additional file 4: Figure S4A. In
the group of drugs with small sample size, the method
without batch effect correction resulted in higher pro-
portions of drugs having the same drug ranked within
top 3 in connectivity mapping between shared genes of
CMAP and LINCS dataset.
An increasing trend was observed for the methods that
correct for two to four PCs. When the cut-off rank was
relaxed from top 3 to top 10, similar results were ob-
tained (see Additional file 4: Figure S4B). Similar results
were obtained for FDR cutoff at 5 and 20% (Additional
file 5: Figure S5-Additional file 6: Figure S6). We
Fig. 5 Results of connectivity score analysis with a fixed number of 15 genes with lowest FDR. a, Boxplot of the ranks of the same drug in
connectivity mapping between CMAP and LINCS dataset. b, The proportion of drugs having the same drug ranked within top 3 in connectivity
mapping between shared genes of CMAP and LINCS dataset. The x-axes are grouped by the total sample size in CMAP dataset. The colors
indicate the differential gene expression analysis methods
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emphasize that results shown in Additional file 4: Fig.
S4, Additional file 5: Figure S5 and Additional file 6: Fig-
ure S6 only include the drugs that have at least 10 sig-
nificant genes as indicated by the differential expression
analysis, thus the drug lists varied among different
methods and total sample size groups.
Expression microarray data simulations
We simulated gene expression data from the original
data of nine drugs with varying sample sizes, i.e.
monastrol, LY-294002, colchicine, alprostadil, nocoda-
zole, felodipine, vorinostat, fulvestrant and trichostatin
A, of which the total sample size were 16, 24, 31, 33,
34, 43, 83, 128, and 837, respectively (Table 3). To
address different situations, five simulation scenarios
were applied and summarized in Table 4. These sce-
narios include different number of batches, allocation
ratios and batch effect sizes (see Methods).
Generally speaking, with more PCs added to the
model, more significant genes were found regardless
of the simulation setting applied (Additional file 7:
Figure S7, Additional file 8: Figure S8, Additional file 9:
Figure S9, Additional file 10: Figure S10 and Additional
file 11: Figure S11A), although a few cases (vorinostat is
especially exceptional across all the simulation settings)
demonstrated first an increase, then a decreasing trend
when considering different numbers of PCs with PC2 or
PC3 as the turning point. The increased number of signifi-
cant genes was at the cost of increased number of false
positive results (Additional file 7: Figure S7, Additional file
8: Figure S8, Additional file 9: Figure S9, Additional file
10: Figure S10 and Additional file 11: Figure S11B). The
proportions of false positive results were well con-
trolled for, below or slightly higher than the pre-de-
fined threshold for most of the simulated data when
correcting for one or two PC(s). The only exception
for this phenomenon was observed in the results of
the data simulated from the drug colchicine, for
which the highest proportions of false positive results
were observed in the method without batch effect
correction, and the proportions of false positive re-
sults were only well controlled in the setting of bal-
anced batch design, medium batch effects and FDR at
10% when corrected for one or two PC(s) (Additional
file 8: Figure S8). Notably, the number of simulated
significant genes was small for this drug (Table 3).
Moreover, for the data simulated from monastrol,
which have a sample size smaller than 20, few signifi-
cant results were obtained and proportions of false
positives were extremely low, accordingly (Additional
file 7: Figure S7, Additional file 8: Figure S8, Add-
itional file 9: Figure S9, Additional file 10: Figure S10
and Additional file 11: Figure S11A-B).
Statistical power was generally lower than 20% for
every method analyzed on the simulated data with
total sample size smaller than 40, even without add-
ing the additional simulated batch effects (Additional
file 7: Figure S7, Additional file 8: Fig. S8, Additional
file 9: Figure S9, Additional file 10: Figure S10 and
Additional file 11: Figure S11C). For the data with
total sample size larger than 40, with the increase of
the total sample size, the statistical power increased,
except for the data simulated from the real data of
the drug fulvestrant.
Examining the simulation results of the data simu-
lated from the real data of the drugs vorinostat and tri-
chostatin A, we observed that: i) when the medium
batch effects simulated from principal component load-
ings were added to the expression data, the power de-
creased by 10% for the method without batch effect
correction, while the power of the methods correcting
for two and three PCs only decreased by no more than
3% (Additional file 7: Figure S7 and Additional file 8:
Figure S8C); ii) increasing of FDR value from 10 to 20%
resulted in small increase in proportion of false posi-
tives (1–4%) in exchange for a higher increase in power
Table 3 Simulated drug profiles
Drug Drug
samples
Control
samples
Total sample
size
DEG in unsimulated
data
monastrol 8 8 16 22
LY-294002 12 12 24 403
colchicine 6 25 31 21
alprostadil 7 26 33 18
nocodazole 5 29 34 1060
felodipine 7 36 43 72
vorinostat 12 71 83 5145
fulvestrant 40 88 128 1453
trichostatin
A
128 709 837 6481
Note: drug, the drug of which the simulated data were generated from. DEG,
differentially expressed genes, that is, the number of genes that were
simulated to be differentially expressed due to the drug effects
Table 4 Simulation scenarios
Scenario name Batch effect
size parameter
FDR
threshold
Batch
allocation
difference
No batch effect 0 0.1 0
Medium batch effect, balanced
design
2 0.1 0
Large batch effect, balanced
design
4 0.1 0
Medium batch effect,
unbalanced design
2 0.1 0.3
Medium batch effect, balanced
design, larger FDR threshold
2 0.2 0
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(5–10%) (Additional file 8: Figure S8B-C and Additional
file 11: Figure S11B-C); iii) compared to the results of
the simulation with medium batch effect, when large
batch effects were added to the data, the power of
the method without batch effect correction and the
method correcting for only one PC decreased
substantially (> 15%), while the power of the method
correcting for two and three PCs remained similar (< 5% dif-
ference) (Additional file 8: Figure S8C and Additional file 9:
Figure S9C); iv) similar results were obtained when an unbal-
anced batch design was imposed (Additional file 8: Figure S8
and Additional file 10: Figure S10).
Discussion
The present study investigated differential expression
analyses with different batch effect correction methods
on the publicly available datasets CMAP and LINCS.
CMAP was used to obtain drug signatures, which are
critical in downstream analyses of drug repositioning.
The quality of the drug signatures generated by each
method was further analyzed by connectivity mapping
between the CMAP and the LINCS datasets on the sub-
set of shared drugs and genes between the databases.
Lastly, a simulation study was performed to compare
models with different numbers of PCs included as covar-
iates as well as the null models fitted by limma. To our
knowledge, this study is the first to evaluate batch effects
by conducting connectivity mapping between two data-
sets on shared drugs which can be seen as a gold-stand-
ard analysis, as the drugs should match up exactly if
data is reliable.
We believe that our comparison covers at least con-
ceptually a wide range of techniques employed in
practice as many characteristics are shared among
methods. Depending on whether batch information
has to be explicitly specified or not, a method can be
classified into being a supervised or unsupervised
method. It is therefore critical that either batch infor-
mation is correctly specified or a method can identify
this information automatically. If the batch informa-
tion is not well identified, the methods could under-
or overcorrect depending on whether too little or too
much information is used. The method correcting for
batch id is the prototype of a supervised method that
might undercorrect, as additional variations may be
present within batches. PCA is an unsupervised batch
effect correction method. As used in this paper, it
might overcorrect as all genes were included in the
estimation of PCs which includes those exhibiting
true biological effects. Finally, LEAPP is an unsuper-
vised method that might be optimal if the method
achieves to separate genes represent batches from
genes exhibiting biological effect. Arguably most
methods fall into these broader categories and our
results allow to judge whether conceptual trade-offs
translate into results from data analyses, and
simulations.
We showed that batch effect correction methods had a
significant impact on the results of the gene expression
analysis, and because the disease signature is directly
compared to the results of the drug signature in gene-
expression based drug repositioning [4], the downstream
analyses of drug repositioning will likely be compro-
mised in the case of uncorrected batch effects in the
drug signature. This was demonstrated by i) the exist-
ence of significant batch effects as illustrated by PCAs;
ii) that the generated gene signature sizes varied sub-
stantially between different batch effect correction
methods; and iii) that in the group of drugs with total
sample size larger than 40, we observed significant im-
provement in the relative ranks for batch effect correc-
tion methods compared to the null model in the analysis
of connectivity mapping with a fixed number of 15
genes, that is, we were closer to the truth with batch ef-
fect correction compared to no batch effect correction.
Note that we also conducted the analysis of connectivity
mapping with sets of significant genes to mimic the ana-
lysis in practice (Additional file 4: Figure S4, Additional
file 5: Figure S5 and Additional file 6: Figure S6), how-
ever, the plots of the results should not be taken as com-
parisons between the methods, since each method and
sample size group had different list of drugs being ana-
lyzed by the gene set enrichment analysis depending on
whether the drug produced a sufficiently large enough
signature size (≥ 10). Therefore, the results depend
highly on the average quality of the drug signatures
which varied among the methods and prevents a fair
comparison. For example, it is highly likely that the aver-
age quality of the drug signatures produced by the
method without batch effect correction was higher only
because the drug signatures with higher quality of genes
(of evident signals) were found by the method, and thus
the proportion of successful discoveries was higher for
the method. This is supported by the fact that the
method without batch effect correction found the fewest
drugs with at least 10 significant genes among all the
methods (Fig. 4).
In connectivity mapping, we showed that most of the
CMAP drugs of total sample size smaller than 40 are
not retrievable from LINCS (not among the connectivity
score rank top 3). Therefore, the drug signatures gener-
ated by the differential expression methods investigated
in this study were probably not reliable when the total
sample size was smaller than 40, in the sense that the
drug signatures are probably unable to perform well in
downstream analysis of drug repositioning, no matter
whether batch effects were corrected for or not. This
was also supported by the simulation results, where we
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observed extremely low power in every simulated data
with total sample size smaller than 40. Therefore, we
conclude that more than 40 total samples are needed to
generate reliable drug signatures from CMAP data.
The LEAPP method was not effective in our analysis—
at least in the way we used it—although the method is
theoretically advantageous and convenient (Sun et al.
[20]). The differential expression results generated by
the LEAPP method show little agreement with the
limma methods, but we were unable to validate the
quality of the drug signatures generated by the method
or determine if the method was better in analyzing the
CMAP dataset than the limma methods. The LEAPP
method generated many estimates being exactly 0 in
both the CMAP and the LINCS datasets, which pre-
vented us from running the gene set enrichment ana-
lysis. Most likely, sample size in our application was too
low for LEAPP to work reliably but we did not investi-
gate this hypothesis in detail. We were unable to run
simulations for LEAPP as it was too time consuming.
Among the limma methods, correcting for two and
three PCs performed equally well as correcting for batch
id when analyzing data with large sample size, as was in-
dicated by the analysis of connectivity mapping. Never-
theless, the method adjusting for PCs has the potential
to outperform the method adjusting for batch id for the
following reasons: i) PC scores are continuous, which
could detect relatively small technical differences within
batches, such as, the temperature gradient on plates, and
thus could have benefits over categorical variables like
batch id; ii) PCs can be directly generated from the gene
expression data so that the researcher does not need to
rely on accurate batch labels; iii) PCs can be analyzed in
a more refined fashion. For example, control genes could
be introduced in the analysis, as is applied in the RUV-2
method [19]. Secondly, non-linear relations could be in-
troduced to the model with PCs accompanied by model
selection of non-linear terms.
In the simulation study, correcting for two PCs
achieved relatively higher power and fewer false positives
than correcting for other numbers of PCs in the simu-
lated data of sufficiently large total sample size. In gene
set enrichment analysis, though, correcting for three PCs
performed relatively better. Based on the results, we rec-
ommend correcting for two or three PCs in data with
sufficiently large sample size.
The simulation study also suggested less conservative
FDR cutoff value should be considered. We speculate
that the increase of the FDR threshold could increase
power with small trade-off on the proportions of false
positives, which might improve the results in the gene
set enrichment analysis.
It is likely that PCs are unstable when the sample size
is small, which may be one of the reasons that it did not
perform well in data with small sample size in our ana-
lysis. PC correction can be adapted by applying weights
in PCA by borrowing information from other data, such
as, data from the same batch or by shrinking the covari-
ance matrix towards the identity matrix [22]. We here
only investigated raw PCs and modifications will be
studied in future research.
In our study, we performed the analysis of connect-
ivity mapping between two databases on the shared
drugs. On the one hand, we implemented the prac-
tical procedure of computational drug repositioning.
On the other hand, we provided a method to evaluate
the quality of the drug signatures generated by differ-
ential expression methods, where we sought to find
the same drugs back in the top of the lists ordered
by the connectivity scores. Because the same drug is
expected to affect the same cell line in different data-
bases similarly, this could be considered a “gold
standard”. However, there were also some limitations
to this approach. Firstly, not all the cell types used in
CMAP are available in LINCS. The analysis was done
without matching the cell types between the two da-
tabases. Although ignoring the cell types may add
noise to the analysis, the results are unbiased and ro-
bust. On the other hand, matching cell types would
remove several samples from CMAP and thus take
the analysis further away from real applications. Sec-
ondly, we imposed a fixed number of 15 genes in the
signature for the analysis, which was rather small and
may negatively affect results. The minimum number
for gene set enrichment analysis was suggested to be
25 so as to avoid inflation of scorings [23]. We chose
to standardize on 15 genes because most drugs could
not identify at least 25 genes below the FDR cutoff.
Thirdly, point estimates of fold changes were used to
calculate the connectivity scores, which did not ac-
count for the uncertainties in the estimates. This
could be addressed by for example weighting esti-
mates according to p-values, or introducing another
parameter determining the degree of weighting.
We observed that the power of the differential ex-
pression analyses on the data simulated from fulves-
trant, which has a large total sample size (83), was
extremely low. As can be seen in Additional file 12:
Figure S12, the standard errors of the effect estimates
of fulvestrant seem to be high, indicating a large
noise component. The proportions of false positive
results were not controlled at the pre-defined signifi-
cance level in some cases despite the Benjamini
Hochberg correction. No special patterns were ob-
served in the histograms of the P-values for these
cases (Additional file 13: Figure S13 and Additional
file 14: Figure S14). Further research is needed to
understand this phenomenon.
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In the simulation study, we simulated both the case
and control data under the null hypothesis by extracting
the variance-covariance matrix from the real data of the
vehicle controls, thereby capturing both biological and
batch effects in the covariance matrix. Instead of inter-
preting such data as batch-effect free, we see it as a
starting point for the simulations with a realistic covari-
ance structure which is not necessarily identical to that
of the actual drug. Moreover, the drug effects simulated
were based on point estimates of differential expression
analysis of real data which only reflect the truth up to
uncertainty in estimates. The absence of further modifi-
cations of drug effects implies that some effects are over-
estimated and are exaggerated in the simulations. In the
simulations, where the simulated drug effects were small,
the power to detect the differences between simulated
cases and simulated controls was expected to be small as
well. Lastly, the batch effects were simulated from the
first two PCs of the PCA, which is probably the reason
that the method correcting for two PCs performed bet-
ter than the other methods. On the other hand, the real
data analysis supports the more general conclusion put
forward in this discussion.
Conclusions
Our study highlighted the importance of batch effect
correction in computational drug repositioning, espe-
cially in generating gene expression signatures with the
CMAP dataset, which has been used in at least 2800
studies. We recommend exercising caution in selecting
proper batch effect correction methods. In applying the
methods discussed in this study, sufficient sample size is
essential to assure the validity of results. It is advisable
to adjust for two or three PCs in the models fitted by
limma when the total sample size is large enough (at
least > 40 drug and controls combined), which applies to
most of the drugs in LINCS (among the drugs shared
with CMAP, 99.8% have total sample size larger than
40). However, for drugs of smaller total sample size, if
analyzed with the methods discussed in this paper, the
results should be interpreted with caution. Dealing with
small sample sizes seems to require more method
development.
Future work can include: i) applying weights and/or
regularization in PCA on data with small sample size; ii)
evaluating the optimal number of genes to be used in
gene set enrichment analysis; iii) conducting simulations
with various sizes of drug effects.
Methods
Data sources
CMAP database (build 2) was downloaded using the
PharmacoGx package (version 1.6.1) [24]. Pre-processing
of the database included Robust Multiarray Average
(RMA) normalization, followed by correction for be-
tween platform differences using combat function in the
SVA package (version 3.10.0) [25]. The CMAP dataset
consists of 1309 distinct drugs. The number of genes in
each gene expression profile is 11,833. In total, 7056
samples, including the bioactive perturbagens and their
corresponding vehicle controls, were profiled. There are
overall 302 batches, performed in five kinds of cell type.
The LINCS database in the level 3 format was ob-
tained from the NCBI Gene Expression Omnibus (GEO)
dataset (GSE92742), which was pre-processed by invari-
ant set scaling and quantile normalization [12]. The
number of genes provided at this level is 12,328 in total,
out of which 11,350 were imputed from 978 landmark
genes. However, we only included the 978 directly mea-
sured genes in our analysis. The samples profiled in the
cell lines that had not been used in CMAP were ex-
cluded. Conversion from Entrez gene identifiers to
Ensembl gene identifiers used by the CMAP database
was performed using the bioMart package (version
2.32.1).
Data cleaning
To avoid the effect of influential observations on the
analyses, for every drug, samples were excluded if the
concentration value used for the perturbation was more
than 1.5 times the interquartile range above the third
quartile or below the first quartile of the concentration
values. The vehicle controls, i.e. samples containing only
solvents for the active drug, from the same batches as
the excluded drug samples were excluded as well. The
total sample size of certain drug is therefore the sum of
the number of drug samples and the number of the cor-
responding vehicle controls after exclusion.
To reduce the computational burden of the analyses
while increasing the statistical power, we applied non-
specific gene filtering by removing genes with coeffi-
cients of variation outside the 20 and 80% quantiles (co-
efficient of variation is the ratio of the standard
deviation to the mean).
Principal component analysis
PCA was used both as a descriptive tool to evaluate the
existence of batch effects and as a correction method
[19]. Scores of the PCs were extracted, which were sub-
sequently added as covariates up to the first four compo-
nents into the differential gene expression models.
Plotting the scores is a way of visualizing batch effects.
This analysis was performed using the built-in R func-
tion prcomp.
Differential expression analysis
Concentrations of the vehicle controls were set to zero,
while the concentrations of the drugs were rescaled to
Zhou et al. BMC Bioinformatics          (2019) 20:437 Page 10 of 14
molar concentrations, and subsequently loge plus one
transformed (i.e. the mean of the log-transformed con-
centrations of vehicle controls was zero).
Batch effect correction methods
Linear modeling with limma
Limma is an R/Bioconductor software package that fits
linear model to each row that represents a gene in an
gene expression matrix, as well as borrows information
from the other genes analyzed, thus providing more reli-
able statistical results [26].
The model without batch effect correction:
yi ¼ β0 þ β1Xi þ ξ i;
where yi is the expression value of sample i, β0 is the
intercept, β1 is the drug effect, Xi is loge plus one trans-
formed molar concentrations of the drug, ξi is the re-
sidual for sample i.
We assessed the following batch effect correction
methods that adjusted for covariates in linear models fit-
ted by the limma package (version 3.32.5).
Blocking batch information in linear model By in-
cluding batch id (corresponding to the plate used to in-
cubate the sample) while fitting linear model, this
method adjusts the mean of the expression levels by the
contrast of a batch with the reference batch.
yi ¼ β0 þ β1Xi þ β2Z1i þ…þ β jþ1Zji þ ξ i;
where yi is the expression value of sample i, β0 is the
intercept, β1 is the drug effect, Xi is loge plus one trans-
formed molar concentrations of the drug, β2,..., βj + 1 are
the coefficients of the dummy variables for batch IDs,
Z1i, ..., Zji are the dummy variables for batch IDs (j in-
dexes the batches) of sample i, ξi is the residual for sam-
ple i.
Correcting for principal components in linear model
The method adjusts for batch effect by including several
PCs starting from the first as covariates while fitting the
linear model. These PCs are believed to capture batch
effects under the assumption that the variation caused
by batch effects is much larger than the variation caused
by drug effects. The method is similar to RUV-2 but
without applying the PCA on negative control genes, as
drug specific control genes have not been determined.
The optimal number of PCs needed to capture the batch
effect is part of the evaluation. In formula.
yi ¼ β0 þ β1Xi þ β2C1i þ…þ βpþ1Cpi þ ξ i;
where yi is the expression value of sample i, β0 is the inter-
cept, β1 is the drug effect, Xi is loge plus one transformed
molar concentrations of the drug, β2,..., βp are the
coefficient of the principal components, C1i, ..., Cpi are the
scores of the first 1 to p principal component(s) of sample
i, p = 1, 2, 3 or 4, ξi is the residual for sample i.
Empirical Bayes procedures implemented in the limma
package was employed to moderate estimated gene vari-
ances generated by limma models.
The latent effect adjustment after primary projection
method
The LEAPP method attempts to automatically separ-
ate batch effects from the biological effects of interest
by an estimation procedure. An attractive feature of
the method is that it obviates the need of a list of
control genes. The model estimates latent vectors cor-
responding to PCs so that residuals become uncorre-
lated, i.e. clustering in the data is removed. The
number of latent variables is subject to variable selec-
tion and the method can be seen as PCA correction
that searches control genes implicitly. The detailed
description of the method can be found in the paper
of Sun, et al. [20]. The analyses was conducted with
LEAPP package (version 1.2). For the LEAPP func-
tion, we entered loge plus one transformed concentra-
tions as primary variables, assuming sparsity of the
primary parameter. IPOD algorithm in Owen and She was
applied to enforce sparsity [27]; hard thresholding was
used in the algorithm to ensure robustness.
The resulting P-values were adjusted with Benjamini-
Hochberg approach to control the false discovery rate
(FDR). The significance level is defined at FDR 10% but
other commonly used FDR levels (5, 20%) were also
assessed.
Connectivity mapping
The connectivity scores were calculated by Gene Set
Enrichment Analyses (GSEA) with the function Con-
nectivityScore in PharmacoGx package (version 1.6.1)
[28]. The Benjamini-Hochberg FDRs were recalculated
for CMAP based on the genes shared with LINCS,
after which the estimates of the 15 genes with lowest
FDR values were extracted and compared to the cor-
responding set of genes in the LINCS database. For
each drug in the CMAP dataset, we ranked the list of
drugs in the LINCS dataset according to the order of
the connectivity score from highest to lowest, and the
rank of the corresponding same drug in LINCS data-
set was extracted. Wilcoxon signed-rank test was used
for comparing the resulting ranks between methods.
Additionally, instead of using a fixed number of genes
to calculate the connectivity scores, the same analysis
was performed by only using the estimates of the dif-
ferentially expressed genes defined by certain FDR
threshold, so as to mimic the procedure of drug and
disease connectivity mapping. The connectivity score
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was only calculated when the number of differentially
expressed genes exceeded 9, which is the minimum
required by the GSEA function. Different FDR cut-off
values (FDR ≤ 5%, FDR ≤ 10% and FDR ≤ 20%) to de-
termine significance were assessed.
Expression microarray data simulations
Simulation studies were performed to compare i) the
null model fitted by limma, and ii) the models fitted
by limma with different number of PCs included as
covariates. We based our simulated data on the cor-
relation structure of real data corresponding to a rep-
resentative selection of drugs and its vehicle controls.
By simulating the same sample size as for the real
data, simulations closely follow a realistic setting (sig-
nificance level defined at FDR ≤ 10%). Simulated data
under the null hypothesis were generated from real
expression data of vehicle controls, with noise added
by sampling from multivariate distribution with mean
0 and covariance matrix extracted block-wise from
the data (1000 genes per block). Afterward drug ef-
fects extracted from the linear models fitted by limma
on log-transformed drug concentration and adjusted
for two PCs, were added to the simulated treatment
group. Further, rescaled loadings of the first two PCs
from the PCA on the real expression data of both the
treatment and the control groups were used to simu-
late batch effects. The rescaling factors were 0, 2 and
4, representing no, medium and large batch effects re-
spectively. The batch effects were simulated in four
scenarios: 1) without loadings, 2) only the first princi-
pal component (PC1), 3) only the second principal
component (PC2), and 4) PC1 and PC2. These four
scenarios were always applied to the complete simu-
lated case data, but the percentage applied to the
control data thus modified depending on whether the
batch effect was simulated as balanced or not. Thirty
percent differences in batch allocation were imposed
to simulate unbalanced designs. FDR cutoff values at
10 and 20% were evaluated. The simulation was con-
ducted 10 times per drug and per setting.
Additional files
Additional file 1: Figure S1. Score plots of the first two principal
components for four typical drugs (A, B, C, D). Colors indicate batch
(plate id) and shapes indicate cell type. (PDF 1116 kb)
Additional file 2: Figure S2. Using connectivity mapping to evaluate
batch effect correction methods illustrated by ciclopirox. First, both CMAP
and LINCS underwent the differencial expression analyses with the same
batch effect correction methods, which resulted in drug signatures for all
the drugs; second, the drug signature of ciclopirox in CMAP matched to
all the drug signatures in LINCS, and the resulted connnectivity scores
were ranked, where we expect that ciclopirox appears within the top
three of the ranked list when the drug signature generated by the
method is of high validity and good quality. (PDF 85 kb)
Additional file 3: Figure S3. Results of connectivity score analysis with
a fixed number of 15 genes with the lowest FDR. The y axis is the
proportion of drugs having the same drug ranked within top 10 in
connectivity mapping between shared genes of CMAP and LINCS
dataset. The error bars are the 95% confidence levels as estimated by
binomial test. The x-axis is grouped by the total sample size in CMAP
dataset. The colors indicate the differential gene expression analysis
methods. (PDF 488 kb)
Additional file 4: Figure S4. Results of connectivity score analysis with
all significant genes (FDR ≤ 10%). Only drugs with at least 10 significant
genes yielded were included in the analysis. The y axis is the proportion
of drugs having the same drug ranked within top 3 or 10 in connectivity
mapping between shared genes of CMAP and LINCS dataset. The error
bars are the 95% confidence levels estimated by binomial test. The x-axis
is grouped by the differential gene expression analysis methods. The
colors indicate the total sample size in CMAP dataset. (PDF 1461 kb)
Additional file 5: Figure S5. Results of connectivity score analysis with
all significant genes (FDR ≤ 5%). Only drugs with at least 10 significant
genes yielded were included in the analysis. The y axis is the proportion
of drugs having the same drug ranked within top 3 or 10 in connectivity
mapping between shared genes of CMAP and LINCS dataset. The error
bars are the 95% confidence levels estimated by binomial test. The x-axis
is grouped by the differential gene expression analysis methods. The
colors indicate the total sample size in CMAP dataset. (PDF 1492 kb)
Additional file 6: Figure S6. Results of connectivity score analysis with
all significant genes (FDR ≤ 20%). Only drugs with at least 10 significant
genes yielded were included in the analysis. The y axis is the proportion
of drugs having the same drug ranked within top 3 or 10 in connectivity
mapping between shared genes of CMAP and LINCS dataset. The error
bars are the 95% confidence levels estimated by binomial test. The x-axis
is grouped by the differential gene expression analysis methods. The
colors indicate the total sample size in CMAP dataset. (PDF 1433 kb)
Additional file 7: Figure S7. Results of the simulation study without
batch effects and FDR < 10%. A, log10 transformed number of significant
genes averaged over 10 simulations; B, Proportion of false positives
among the significant genes averaged over 10 simulations; C. the power
of the analysis averaged over 10 simulations. (PDF 95 kb)
Additional file 8: Figure S8. Results of simulation study with medium
batch effects and FDR < 10%. A, log10 transformed number of significant
genes averaged over 10 simulations; B, Proportion of false positives
among the significant genes averaged over 10 simulations; C. the power
of the analysis averaged over 10 simulations. (PDF 95 kb)
Additional file 9: Figure S9. Results of simulation study with large
batch effects and FDR < 10%. A, log10 transformed number of significant
genes averaged over 10 simulations; B, Proportion of false positives
among the significant genes averaged over 10 simulations; C. the power
of the analysis averaged over 10 simulations. (PDF 94 kb)
Additional file 10: Figure S10. Results of simulation study with
medium batch effects, FDR < 10% and unequal allocation of cases and
controls. Medium batch effect simulated with 0.3 differences between
cases and controls. A, log10 transformed number of significant genes
averaged over 10 simulations; B, Proportion of false positives among the
significant genes averaged over 10 simulations; C. the power of the
analysis averaged over 10 simulations. (PDF 94 kb)
Additional file 11: Figure S11. Results of simulation study with
medium batch effects and FDR < 20%. A, log10 transformed number of
significant genes averaged over 10 simulations; B, Proportion of false
positives among the significant genes averaged over 10 simulations; C.
the power of the analysis averaged over 10 simulations. (PDF 94 kb)
Additional file 12: Figure S12. Negative log 10 of P-values plotted
against absolute estimates of extracted drug effects of felodipine,
fulvestrant and vorinostat. (PDF 391 kb)
Additional file 13: Figure S13. Histograms of P-values resulted from
differential expression analyses on one set of data simulated from
colchicine with balanced batch design and median batch size (parameter
settings see Table 4) at FDR≤ 0.1. The differential expression analyses: A)
limma + null model; B) limma + 1 PC; C) limma + 2 PCs; D) limma + 3
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PCs; E) limma + 4 PCs. Abbreviations: PC, principal component; MPFP,
mean proportion of false positive results. MPFP, mean proportion of false
positives among the significant genes. (PDF 1648 kb)
Additional file 14: Figure S14. Histograms of P-values resulted from
differential expression analyses on one set of data simulated from
vorinostat with balanced batch design and median batch size (parameter
settings see Table 4) at FDR≤ 0.1. The differential expression analyses: A)
limma + null model; B) limma + 1 PC; C) limma + 2 PCs; D) limma + 3
PCs; E) limma + 4 PCs. Abbreviations: PC, principal component; MPFP,
mean proportion of false positive results. MPFP, mean proportion of false
positives among the significant genes. (PDF 1242 kb)
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